Blueprint Medicines’ focus on Ayvakit continues to pay off, which has ample untapped revenue potential in advanced and indolent systemic mastocytosis. Additionally, their pipeline includes other ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results